2006 and Biosimilars - Drug Discovery Digest

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Drug Channels

OCTOBER 3, 2023

Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.

Four Crucial Questions about the Humira Biosimilar Price War

Drug Channels

JULY 18, 2023

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup

Drug Channels

JANUARY 9, 2024

This year, Humira and its 13 biosimilars will provide the most intriguing formulary drama. Unfortunately, the gross-to-net bubble will remain a fixture for this category, despite a price war led by almost half of the biosimilars. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Biosimilars

Biosimilars Pharmacy Production Drugs

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

Drug Channels

OCTOBER 18, 2022

The biosimilar boom for provider-administered drugs continues to accelerate. Net prices in therapeutic classes with biosimilar competition have declined by 60% or more over the past few years. Some major biological reference products have now lost a majority of their unit sales to their biosimilars. drug distribution.

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars (rerun)

Drug Channels

DECEMBER 11, 2023

One update: CVS Caremark's 2024 formulary for patient-administered autoimmune products prefers: Humira Hyrimoz (the high WAC Sandoz biosimilar) adalimumab-adaz (the unbranded, low WAC Sandoz biosimilar) Perhaps coincidentally, Sandoz products are marketed by Cordavis, the new business described in today's rerun.

The Biosimilar Boom and the Coming Humira Price War (Video)

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Prices are dropping while adoption accelerates.

Biosimilars

Biosimilars Marketing Production Drugs

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars

Biosimilars Pharmacy Marketing Drugs

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

Drug Channels

JANUARY 10, 2023

Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. I also note some troubling research on the patient impact of exclusions—although much remains unknown.

Biosimilars

Biosimilars Pharmacy Production Drugs

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha

Drug Channels

FEBRUARY 7, 2023

As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Production Drugs Marketing

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars (rerun)

Drug Channels

MARCH 28, 2023

Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. I also note some troubling research on the patient impact of exclusions—although much remains unknown.

Biosimilars

Biosimilars Pharmacy Production Drugs

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup (rerun)

Drug Channels

APRIL 3, 2024

The 2024 formularies described below should boost biosimilar adoption. As a new Biosimilar Council report shows , Humira retained 99% of market share in late 2023, despite being more expensive than its biosimilars. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars

Biosimilars Pharmacy Production Drugs

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

Drug Channels

OCTOBER 14, 2022

Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Read on for Steve’s insights. d/b/a Drug Channels Institute.

Betting Big on Biosimilars: How Evolving Market Dynamics Will Impact Patient Access

Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Marketing Drugs

Drug Channels News Roundup, October 2023: CVS & Humira Biosimilars, GLP-1 G2N Bubble, 340B Abuses, Rite Aid's Endgame, Mark Cuban Update, and an Epic Meetup

Drug Channels

OCTOBER 31, 2023

CVS Health frightens all but one Humira biosimilar maker away from its formulary. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. It's time for a super-sized Halloween roundup of wicked Drug Channels ’ tales. This month’s tricks and treats: Spooky! The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us.

Biosimilars

Biosimilars Pharmacy Drugs

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies

Drug Channels

SEPTEMBER 13, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha (rerun)

Drug Channels

MARCH 30, 2023

So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version. As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Biosimilars

Biosimilars Pharmacy Production Drugs

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies (rerun)

Drug Channels

DECEMBER 12, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. P.S. Join my nearly 30,000 (!)

Biosimilars

Biosimilars Pharmacy Drugs Marketing

Drug Channels News Roundup, April 2023: OptumRx’s Biosimilar Nonsense, Accumulator Inequity, Amazon Redux, AFPs, and My Meeting with Mark Cuban

Drug Channels

APRIL 25, 2023

While we wait for the Phillies turnaround, let’s oil up our gloves, lace up our cleats, and run the bases around this month's biggest hits: Foul ball : OptumRx prefers higher prices for the first Humira biosimilar Strikeout : Copay accumulators hurt health equity Bench warmer : Surprise? d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Drugs Pharmacy

The Booming Biosimilar Market of 2020

Drug Channels

OCTOBER 6, 2020

The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As I predicted last year, newer biosimilars are being adopted quickly, and their prices are declining rapidly.

Biosimilars

Biosimilars Marketing Regulations FDA

Drug Channels News Roundup, August 2022: Gov. Dean vs. Maximizers, Cancer vs. Copays, Specialty Drug Trends, Biosimilar Transitivity, and Dr. G. vs. PBMs

Drug Channels

AUGUST 23, 2022

on key specialty pharmacy trends Evidence for biosimilar-to-biosimilar switching Plus, Dr. Glaucomflecken takes on PBMs! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. P.S. Join my more than 31,000 LinkedIn followers for daily links to neat stuff. d/b/a Drug Channels Institute.

Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira (rerun)

Drug Channels

APRIL 19, 2022

An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars. Anyone want to tell him about the Express Scripts formulary for insulin biosimilars? Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars

Biosimilars Production FDA Drugs

Drug Channels News Roundup, May 2023: 340B Shame, OptumRx vs. Humira Biosimilars, ICER on White Bagging, Hospitals vs. Taxes, and Dr. G

Drug Channels

MAY 30, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Speaking of PBMs, be sure to join me for my new live video webinar, PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding , on June 23, 2023, from 12:00 p.m. to 1:30 p.m. Click here to learn more and sign up. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Hospitals Pharmacy Drugs

The Booming Biosimilar Market of 2020 (rerun)

Drug Channels

DECEMBER 17, 2020

Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As you will see below, Dr. Gottlieb was right.

Biosimilars

Biosimilars Marketing Regulations FDA

Drug Channels News Roundup, February 2022: Mark Cuban vs. PBMs, MDs on Humira Biosimilars, States vs. PBMs, 340B Transparency, and Health Insurer Humor (?)

Drug Channels

FEBRUARY 28, 2023

In this issue: Mark Cuban explains his anti-PBM strategy What physicians think about Humira biosimilars States go after PBMs HHS is confused about 340B transparency Plus, The Onion tests your knowledge of United Healthcare’s policies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. No promises about future articles.

Biosimilars

Biosimilars Drugs

Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira

Drug Channels

NOVEMBER 9, 2021

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc.

Biosimilars

Biosimilars Production FDA Drugs

Drug Channels News Roundup, October 2022: Mark Cuban on PBMs, Walgreens & 340B, Biosimilar Boom Update, Physicians vs. UM, and Wellness at Walgreens

Drug Channels

OCTOBER 25, 2022

Sink your fangs into Amgen’s fantastic new report on the biosimilar boom Wicked! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Mark Cuban tells ghost stories about PBMs. Walgreens terrifies Wall Street with its 340B losses. Physicians think payers cast evil utilization management spells. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Drugs Pharmacy

Drug Channels News Roundup, June 2024: Cordavis Humira Update, OptumRx’s New Biosim Biz, Generic Drugs' Wild Ride, IRA Predictions, and Dr. G on Med School

Drug Channels

JUNE 25, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Happy 248th birthday, America! Attendance will be limited, so click here to request an invite for our March 2025 event. All rights reserved. This Feed is for personal non-commercial use only.

Biosimilars

Biosimilars Drugs Pharmacy

Drug Channels News Roundup, April 2024: CVS’s Humira Strategy, White Bagging “Savings,” IRA vs. Part D Plans, Walgreens Specialty Update, Pharmacies vs. GoodRx, and Oncology Fun

Drug Channels

APRIL 29, 2024

April is over, so it's time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Biosimilars Drugs

Drug Channels News Roundup, March 2022: UM and Health Equity, Insurers ? White Bagging, Biosimilar Boom, A New Angle on Copay Support, and the Pharmacy Metaverse

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. CVS Health takes the red pill. to 1:30 p.m.

Biosimilars

Biosimilars Pharmacy Drugs

Drug Channels News Roundup, October 2021: PBMs’ Oncology Exclusions, Biosimilar Boom, BCBS vs. Hospitals, U.S. vs. the World, and CRISPR Comedy

Drug Channels

OCTOBER 27, 2021

It’s the biosimilar boom! Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! Brrr.did you hear that? Believe it or not, U.S

Drug Channels News Roundup, May 2024: CVS & Cordavis & Humira, 340Boom, AFP Slowdown, Asembia Wrap-Up, and GLP-1 Humor

Drug Channels

MAY 29, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Click here to learn more and reserve your spot at the June 21 event. All rights reserved.

Biosimilars

Biosimilars Drugs Marketing

Drug Channels News Roundup, June 2021: Amazon's Latest, Patients vs. Accumulators, Generics & Biosimilars, 340B Games, and a Hospital Road trip

Drug Channels

JUNE 27, 2021

on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. P.S. Please join the nearly 12,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.

Biosimilars

Biosimilars Hospitals Pharmacy Vaccine

Drug Channels News Roundup, August 2021: OptumRx’s New GPO, Pharmacy DIR Fees, State Biosimilar Laws, UM Views, and a Newspaper Delivers

Drug Channels

AUGUST 25, 2021

Time to pack away the bathing suit and get serious again—with these curated curiosities combed from the now-barren Drug Channels beach: OptumRx joins the PBM GPO game Pharmacy DIR fees hit $11 billion A terrific resource on state biosimilar laws Patient views on utilization management Plus, my social media success…from a (print) newspaper ad!

Biosimilars

Biosimilars Pharmacy Drugs Research

Drug Channels News Roundup, July 2021: Stingy Hospitals, Biosimilars & Part B, Hep C Drug Prices, Costco vs. Part D, and MBA Funny Business

Drug Channels

JULY 27, 2021

In this issue: The top 10 stingiest hospitals Medicare Part B's savings from biosimilars What happened to hepatitis C drug costs and rebates? Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. Let’s cut through the summer haze with our refreshing breeze of articles and insights. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Hospitals Drugs

Surprise! Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs

Drug Channels

FEBRUARY 21, 2024

Just another IRA-inflicted hit for biosimilars? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Below, I explain why the IRA will encourage Part D plans to prefer high-list, high-rebate specialty drugs , even as the government and manufacturers will prefer a low-list-price version.

Biosimilars

Biosimilars Drugs Government Production

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment. Read on for Saket’s insights.

Drug Channels News Roundup, May 2020: COVID-19 and Formularies, Retail-to-Mail Trends, ABC on Biosimilars, and Social Distancing the CVS Way

Drug Channels

MAY 27, 2020

Before you venture outside for your lockdown barbeque, check out these noteworthy items off the Drug Channels grill: Payers predict how COVID-19 will affect formularies Our analysis of the 2020 retail-to-mail shift AmerisourceBergen profiles biosimilars Plus, CVS pharmacy offers a clever way to measure appropriate social distancing.

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions

Drug Channels

JANUARY 19, 2022

Below, I highlight five observations about this year’s lists, including unexplainable differences in how PBMs handle specialty drugs, biosimilars, and insulin. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Let me know what you think by commenting below or on social media. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Pharmacy Production Drugs

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions (rerun)

Drug Channels

APRIL 20, 2022

Below, I highlight five observations about this year’s lists, including unexplainable differences in how PBMs handle specialty drugs, biosimilars, and insulin. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Let me know what you think by commenting below or on social media. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Pharmacy Production Drugs

Drug Channel Implications of the Inflation Reduction Act (NEW Live Video Webinar)

Drug Channels

MARCH 5, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last 90 minutes to accommodate audience questions. Read on for full details on pricing and registration.

Pharmacy

Pharmacy Biosimilars Drugs Marketing

Drug Channels Outlook 2024 (NEW Live Video Webinar)

Drug Channels

NOVEMBER 14, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. He will draw from exclusive information found in DCI's economic reports. Read on for full details on pricing and registration. d/b/a Drug Channels Institute.

Pharmacy

Pharmacy Biosimilars Drugs Marketing

Drug Channels News Roundup, September 2021: Hospitals’ 340B Profits, Drug Prices Deflate, U.S. vs. EU, Amazon vs. CVS, and More Bad Blood for Theranos

Drug Channels

SEPTEMBER 28, 2021

My recent social media topics have included: the ASPE report, biosimilar reimbursement, non-profit hospital shenanigans, HRSA’s reorganization, MTM in Part D, PBMs’ GPOs, pharmacy GPOs, channel strategy, white bagging, and the soothing sounds of pills being counted. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc.

Hospitals

Drug Channels Outlook 2023 (NEW Live Video Webinar)

Drug Channels

NOVEMBER 9, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. After the event, every registrant will receive a link to download the complete slide deck and have an opportunity to watch a replay of the live event. Read on for full details on pricing and registration. d/b/a Drug Channels Institute.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Biosimilars Drugs

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Four Crucial Questions about the Humira Biosimilar Price War

Trending Sources

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars (rerun)

The Biosimilar Boom and the Coming Humira Price War (Video)

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars (rerun)

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup (rerun)

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

Betting Big on Biosimilars: How Evolving Market Dynamics Will Impact Patient Access

Drug Channels News Roundup, October 2023: CVS & Humira Biosimilars, GLP-1 G2N Bubble, 340B Abuses, Rite Aid's Endgame, Mark Cuban Update, and an Epic Meetup

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha (rerun)

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies (rerun)

Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

Drug Channels News Roundup, April 2023: OptumRx’s Biosimilar Nonsense, Accumulator Inequity, Amazon Redux, AFPs, and My Meeting with Mark Cuban

The Booming Biosimilar Market of 2020

Drug Channels News Roundup, August 2022: Gov. Dean vs. Maximizers, Cancer vs. Copays, Specialty Drug Trends, Biosimilar Transitivity, and Dr. G. vs. PBMs

Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira (rerun)

Drug Channels News Roundup, May 2023: 340B Shame, OptumRx vs. Humira Biosimilars, ICER on White Bagging, Hospitals vs. Taxes, and Dr. G

The Booming Biosimilar Market of 2020 (rerun)

Drug Channels News Roundup, February 2022: Mark Cuban vs. PBMs, MDs on Humira Biosimilars, States vs. PBMs, 340B Transparency, and Health Insurer Humor (?)

Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira

Drug Channels News Roundup, October 2022: Mark Cuban on PBMs, Walgreens & 340B, Biosimilar Boom Update, Physicians vs. UM, and Wellness at Walgreens

Drug Channels News Roundup, June 2024: Cordavis Humira Update, OptumRx’s New Biosim Biz, Generic Drugs' Wild Ride, IRA Predictions, and Dr. G on Med School

Drug Channels News Roundup, April 2024: CVS’s Humira Strategy, White Bagging “Savings,” IRA vs. Part D Plans, Walgreens Specialty Update, Pharmacies vs. GoodRx, and Oncology Fun

Drug Channels News Roundup, March 2022: UM and Health Equity, Insurers ? White Bagging, Biosimilar Boom, A New Angle on Copay Support, and the Pharmacy Metaverse

Drug Channels News Roundup, October 2021: PBMs’ Oncology Exclusions, Biosimilar Boom, BCBS vs. Hospitals, U.S. vs. the World, and CRISPR Comedy

Drug Channels News Roundup, May 2024: CVS & Cordavis & Humira, 340Boom, AFP Slowdown, Asembia Wrap-Up, and GLP-1 Humor

Drug Channels News Roundup, June 2021: Amazon's Latest, Patients vs. Accumulators, Generics & Biosimilars, 340B Games, and a Hospital Road trip

Drug Channels News Roundup, August 2021: OptumRx’s New GPO, Pharmacy DIR Fees, State Biosimilar Laws, UM Views, and a Newspaper Delivers

Drug Channels News Roundup, July 2021: Stingy Hospitals, Biosimilars & Part B, Hep C Drug Prices, Costco vs. Part D, and MBA Funny Business

Surprise! Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Drug Channels News Roundup, May 2020: COVID-19 and Formularies, Retail-to-Mail Trends, ABC on Biosimilars, and Social Distancing the CVS Way

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions (rerun)

Drug Channel Implications of the Inflation Reduction Act (NEW Live Video Webinar)

Drug Channels Outlook 2024 (NEW Live Video Webinar)

Drug Channels News Roundup, September 2021: Hospitals’ 340B Profits, Drug Prices Deflate, U.S. vs. EU, Amazon vs. CVS, and More Bad Blood for Theranos

Drug Channels Outlook 2023 (NEW Live Video Webinar)

Stay Connected